Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxOther Accumulated ExpensesPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

VitaNova Life Sciences (YJGJ) Long-Term Deferred Tax (2018 - 2026)

VitaNova Life Sciences (YJGJ) has disclosed Long-Term Deferred Tax for 8 consecutive years, with $147929.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Long-Term Deferred Tax rose 87.52% year-over-year to $147929.0, compared with a TTM value of $147929.0 through Oct 2025, up 87.52%, and an annual FY2025 reading of $102611.0, changed N/A over the prior year.
  • Long-Term Deferred Tax was $147929.0 for Q4 2025 at VitaNova Life Sciences, up from $120008.0 in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $147929.0 in Q4 2025 and bottomed at $1813.0 in Q4 2022.
  • Average Long-Term Deferred Tax over 5 years is $60459.1, with a median of $55522.0 recorded in 2021.
  • The sharpest move saw Long-Term Deferred Tax tumbled 89.45% in 2022, then skyrocketed 1717.54% in 2023.
  • Year by year, Long-Term Deferred Tax stood at $17177.0 in 2021, then crashed by 89.45% to $1813.0 in 2022, then surged by 1717.54% to $32952.0 in 2023, then surged by 139.4% to $78887.0 in 2024, then skyrocketed by 87.52% to $147929.0 in 2025.
  • Business Quant data shows Long-Term Deferred Tax for YJGJ at $147929.0 in Q4 2025, $120008.0 in Q3 2025, and $102611.0 in Q2 2025.